Literature DB >> 26297046

Specific inhibition of mTOR pathway induces anti-proliferative effect and decreases the hormone secretion in cultured pituitary adenoma cells.

Rong Xie1,2,3, Wen-Qiang He1,2,3, Ming Shen1,2,3, Xue-Fei Shou1,2,3, Yong-Fei Wang1,2,3, Wei-Min Bao4,5,6, Yao Zhao7,8,9.   

Abstract

There are some evidences that pituitary tumors may be sensitive to the anti-proliferative effects of mammalian target of rapamycin (mTOR) inhibitors, while the mechanism and effects remains unclear, it is necessary to find if a specific mTOR inhibition, including the blocking of both mTOR function and expression, generate any effects on pituitary adenoma cells. The object of this study was to examine if specific inhibition of mTOR induced anti-proliferative effect and decreased the GH and PRL hormones secretion in GH3 and MtT/E pituitary adenoma cells by using a kind of mTOR shRNA lentiviral vector. The in vitro experiments results showed mTOR shRNA transfection robustly reduced the GH3 and MtT/E cells viability in all durations (1-6 days) we performed, also specifically decreased both GH and PRL hormones external secretion in GH3 cells. Further results suggested that specific inhibition of mTOR decreased the hormones secretion through anti-proliferation effects on GH3 cells and reducing the hormones synthesis, but not through affecting the process of hormones secretion. Then we used phosphatidic acid (PA), a kind of mTOR activator, to promote the cell proliferation and GH and PRL hormones secretion in GH3 cells while the effects were blocked by mTOR shRNA transfection. In addition, we examined in vitro effects of PA treatment and mTOR shRNA gene transfection on major proteins expressed in the mTOR pathway in GH3 cells, and confirmed that PA treatment significant increased the protein levels of pmTOR, pS6 K and p4EBP1 in the scramble shRNA group, while the increase of protein levels was blocked by mTOR shRNA gene transfection. Moreover, mTOR shRNA gene transfection definitely inhibited the expression of mTOR and reduced the expression of pmTOR, pS6K and p4EBP1 in either PA or no PA treatment groups. These findings indicated that specific inhibition of mTOR pathway induced anti-proliferative effect and decreased the GH and PRL hormones secretion in cultured pituitary adenoma cells, which may be a novel promising and potential treatment modality for patients with secreting or non-secreting pituitary adenomas.

Entities:  

Keywords:  Cell proliferation; Hormone secretion; Pituitary adenoma; mTOR pathway

Mesh:

Substances:

Year:  2015        PMID: 26297046     DOI: 10.1007/s11060-015-1895-x

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  31 in total

Review 1.  Pituitary cell lines and their endocrine applications.

Authors:  Guck T Ooi; Neveen Tawadros; Ruth M Escalona
Journal:  Mol Cell Endocrinol       Date:  2004-12-30       Impact factor: 4.102

2.  Blocking glucocorticoid and enhancing estrogenic genomic signaling protects against cerebral ischemia.

Authors:  Michelle Y Cheng; Guohua Sun; Michael Jin; Heng Zhao; Gary K Steinberg; Robert M Sapolsky
Journal:  J Cereb Blood Flow Metab       Date:  2008-09-17       Impact factor: 6.200

Review 3.  PTEN: life as a tumor suppressor.

Authors:  L Simpson; R Parsons
Journal:  Exp Cell Res       Date:  2001-03-10       Impact factor: 3.905

4.  The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.

Authors:  Iwan Beuvink; Anne Boulay; Stefano Fumagalli; Frederic Zilbermann; Stephan Ruetz; Terence O'Reilly; Francois Natt; Jonathan Hall; Heidi A Lane; George Thomas
Journal:  Cell       Date:  2005-03-25       Impact factor: 41.582

Review 5.  Current development of mTOR inhibitors as anticancer agents.

Authors:  Sandrine Faivre; Guido Kroemer; Eric Raymond
Journal:  Nat Rev Drug Discov       Date:  2006-08       Impact factor: 84.694

6.  Cyclin D3 is down-regulated by rapamycin in HER-2-overexpressing breast cancer cells.

Authors:  Pilar García-Morales; Eva Hernando; Estefanía Carrasco-García; María Piedad Menéndez-Gutierrez; Miguel Saceda; Isabel Martínez-Lacaci
Journal:  Mol Cancer Ther       Date:  2006-09       Impact factor: 6.261

7.  A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly.

Authors:  Shlomo Melmed; Richard Sternberg; David Cook; Anne Klibanski; Philippe Chanson; Vivien Bonert; Mary Lee Vance; David Rhew; David Kleinberg; Ariel Barkan
Journal:  J Clin Endocrinol Metab       Date:  2005-04-12       Impact factor: 5.958

8.  Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.

Authors:  Raquel S Jallad; Nina R C Musolino; Luiz R Salgado; Marcello D Bronstein
Journal:  Clin Endocrinol (Oxf)       Date:  2005-08       Impact factor: 3.478

9.  Stable gene transfer to muscle using non-integrating lentiviral vectors.

Authors:  Luis Apolonia; Simon N Waddington; Carolina Fernandes; Natalie J Ward; Gerben Bouma; Michael P Blundell; Adrian J Thrasher; Mary K Collins; Nicola J Philpott
Journal:  Mol Ther       Date:  2007-08-14       Impact factor: 11.454

10.  Estradiol attenuates the focal cerebral ischemic injury through mTOR/p70S6 kinase signaling pathway.

Authors:  Phil-Ok Koh; Jae-Hyeon Cho; Chung-Kil Won; Hyo-Jong Lee; Jin-Hee Sung; Myeong-Ok Kim
Journal:  Neurosci Lett       Date:  2008-03-02       Impact factor: 3.046

View more
  1 in total

1.  mTOR promotes pituitary tumor development through activation of PTTG1.

Authors:  R Chen; J Duan; L Li; Q Ma; Q Sun; J Ma; C Li; X Zhou; H Chen; Y Jing; S Zhao; X Wu; H Zhang
Journal:  Oncogene       Date:  2016-08-15       Impact factor: 9.867

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.